Introduction
============

Chemotherapy has long been an important therapeutic option for several types of malignancies. Doxorubicin (DOX) is one of the most effective antitumor drugs and is used to treat a wide variety of tumors, but severe cardiotoxicity and myelosuppression hamper its clinical dosage regimens [@B1]. To date, numerous nanosized drug delivery systems have been developed to ameliorate the therapeutic performance and biosafety of DOX, including nanoparticles [@B2], liposomes [@B3], micelles [@B4] and dendrimers [@B5]. Nonetheless, cancer therapy currently relying on a single treatment remains unsatisfying due to tumor heterogeneity, drug resistance, or frequent relapses. Considering the complex tumor structures and unique tumor microenvironment (TME), a combination of therapeutic approaches with different drugs and/or mechanisms may cooperatively boost therapeutic efficacy and simultaneously reduce the side effects of cancer chemotherapy [@B6].

Photodynamic therapy (PDT), a minimally-invasive modality that kills cancer cells by the cytotoxic singlet oxygen (^1^O~2~) generated from light-activated photosensitizers (PSs), has attracted broad attention in recent years [@B7]-[@B13]. Based on the attractive antitumor outcomes of PDT, the combined treatment of PDT and chemotherapy may optimize cancer treatment and achieve enhanced antitumor efficacy. However, as an oxygen (O~2~)-requiring therapy, the efficacy of PDT to treat solid tumors is severely affected by the pre-existence of hypoxia in tumors originating from the heterogeneous tumor cell proliferation and dysfunctional vasculature and lymphatic systems [@B14]-[@B20]. So far, to overcome the hypoxia-associated poor response of PDT, a few strategies have been introduced to modify the hypoxic TME and to promote the oxygenation of tumors [@B21]-[@B24]. For instance, artificial blood substitutes, such as perfluorocarbon-based O~2~ nanoparticles used to deliver O~2~ to tumor sites, have been utilized to ameliorate hypoxia, and have shown the improved therapeutic efficacy of PDT [@B25], [@B26]. Nevertheless, developing smart nano-therapeutics sensitive to the TME for better PDT efficacy is still challenging. Recently, various manganese oxide (MnO~2~) nanostructures have been used to relieve tumor hypoxia *in situ* by catalyzing the decomposition of excessive endogenous hydrogen peroxide (H~2~O~2~) and producing O~2~ inside solid tumors thereby significantly promoting treatment outcomes of radiotherapy and PDT [@B27]-[@B31]. Moreover, the reduction product Mn^2+^ offers strong *T*~1~-weighted contrast signal for magnetic resonance imaging (MRI). Thus, MnO~2~-based tumor-targeted nanomaterials can act as both assistant agents for PDT as well as bio-imaging agents.

Nanocarriers could enhance the antitumor efficacy by combining different therapeutic mechanisms and overcoming limitations of single therapeutic approaches. Also, it is highly desirable to create "all-in-one" or "all-for-one" nanosystems that are flexible, multifunctional, and biocompatible [@B32]-[@B34]. In our previous studies on combined anticancer therapy, we developed various types of polymeric micelles, nanoparticles, and polymersomes, which were synthesized by block polymers, such as methoxy poly (ethylene glycol)-poly (D, L-lactide) (mPEG-PDLLA), and cationic PCL grafted poly (ethylene imine) (PCL-g-PEI). Our previous results indicated that the therapeutic efficacy of combination therapy was distinctively superior to either chemotherapy or photothermal therapy (PTT) alone [@B35], [@B36]. We had also fabricated magnetic targeting theranostic nanocapsules to hierarchically assemble superparamagnetic iron oxide nanoparticles (SPIOs), cyanine dye (IR820), and paclitaxel with poly (ε-caprolactone-co-lactide)-b-poly (ethylene glycol)-b-poly (ε-caprolactone-co-lactide) (PCLA-PEG-PCLA). The triblock copolymers exhibited desired formulation properties, especially ideal loading properties of both drugs and nanoparticles [@B37]. However, to the best of our knowledge, reports about co-loading drugs and nanoparticles with one-step fabrication were not sufficient.

Therefore, in this study, to optimize the combination chemotherapeutic efficacy of DOX and the PDT efficacy of photosensitizer chlorin e6 (Ce6), we fabricated a multifunctional polymeric nanoparticle system that could co-deliver Ce6, DOX, and MnO~2~ (Ce6-DOX-MnO~2~ NPs, CDM NPs) for breast cancer theranostics. As illustrated in Figure [1](#F1){ref-type="fig"}, the amphiphilic block copolymer PCLA-PEG-PCLA with appropriate hydrophilic/hydrophobic ratio self-assembled into polymeric nanoparticles. Ce6, DOX, and MnO~2~ were hierarchically loaded into the nanoparticles by a water-in-oil-in-water (W/O/W) double emulsion solvent evaporation method, with hydrophilic DOX and colloidal MnO~2~ in the inner water phase and Ce6 in the middle hydrophobic layer. The resultant nanoparticles exhibited good stability and biocompatibility both *in vitro* and *in vivo*. These theranostic nanoparticles administrated through systemic injection passively accumulated at the tumor location via the enhanced permeability and retention (EPR) effect. After being internalized via endocytosis, encapsulated MnO~2~ reacting with H~2~O~2~, a massive tumor metabolite, to generate O~2,~ which is essential for improving PDT efficacy, and Mn^2+^ for *T*~1~-weighted MRI. To monitor the tumor accumulation of the nanoparticles, we took advantage of the fluorescence and photoacoustic (PA) imaging property of Ce6 and the *T*~1~-weighted MRI property of Mn^2+^. CDM NPs had high efficiency for tumor targeting and showed improved synergistic antitumor outcomes in combined chemotherapy and O~2~ generation-enhanced PDT. By integrating multiple functions in CDM NPs, it is expected that the nanocomposites will be a potential practical, targeted delivery platform for bio-imaging and combination therapy.

Materials and Methods
=====================

Materials
---------

Potassium permanganate (KMnO~4~) was purchased from Sinopharm Chemical Reagent Co., Ltd. Photosensitizer chlorin e6 (Ce6) was obtained from Frontier Scientific (Logan, UT, USA). Poly (allylamine hydrochloride) (PAH, Mw \~17,500), poly (ethylene glycol) (PEG, Mn 4000), D, L-lactide (LA), ε-caprolactone (ε-CL, Mn 114), stannous octoate (Sn(Oct)~2~), poly (vinyl alcohol) (PVA, 87-90%, hydrolyzed, Mw 30,000-70,000) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St Louis, MO, USA) and used without further purification. Doxorubicin hydrochloride (DOX) was commercially available from Meilune Biological Co., Ltd (Dalian, China). Dulbecco\'s modified Eagle\'s Medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco BRL (Carlsbad, CA, USA). Milli-Q water (18.2 MΩ cm) from a Milli-Q Gradient System was used throughout the experiments. PEG was vacuum dried at 60 °C for 12 h before use, and other materials used in this article were of analytical grade. Hoechst 33342, Reactive Oxygen Species (ROS) Assay Kit and Annexin V-FITC Apoptosis Detection Kit were purchased from KeyGEN BioTECH Co., Ltd (Nanjing, China).

Cell Culture
------------

Human breast carcinoma cell line MCF-7 and murine fibroblast cell line NIH 3T3 were obtained from American Type Culture Collection (ATCC) and cultured in high-glucose DMEM with 10% FBS and 1% penicillin-streptomycin at 37 °C in 5% CO~2~ atmosphere.

Synthesis and Characterization of PCLA-PEG-PCLA Copolymer
---------------------------------------------------------

PCLA-PEG-PCLA copolymer with designed LA/ε-CL/PEG molecular weight of 14400/21600/4000 was synthesized by ring-opening polymerization as previously reported [@B37], [@B38]. In brief, specific amounts of ε-CL, LA and PEG were added to a dry round-bottom flask at nitrogen atmosphere. Subsequently, Sn(Oct)~2~ was added to the system under stirring. The reaction was carried out at 130 ℃ for 10 h under nitrogen protection. The resultant copolymers were then purified, vacuum dried to a constant weight, and stored under -20℃ before further use. The obtained PCLA-PEG-PCLA copolymers were characterized by ^1^H-nuclear magnetic resonance spectroscopy (^1^H-NMR, Bruker 400 spectrometer, German) and Fourier transform infrared spectroscopy (FT-IR, Nicolet 6700 FTIR spectrometer, Thermo Fisher Scientific, MA, USA).

Preparation of Colloidal PAH-stabilized MnO~2~
----------------------------------------------

Colloidal MnO~2~ was prepared by directly mixing the aqueous solutions of KMnO~4~ and PAH according to the literature [@B27], [@B39]. Briefly, 18 mL of KMnO~4~ solution (3.5 mg/mL) was mixed with 2 mL of PAH solution (37.4 mg/mL), and the mixture was left for 15 min at room temperature until all permanganate was converted to MnO~2~. The colloidal MnO~2~ formation was confirmed by UV-vis absorption spectroscopy (UV-2600, SHIMADZU, Japan) and X-ray photoelectron spectroscopy (XPS). Colloidal MnO~2~ was washed three times with Milli-Q water using ultracentrifugation (229600 rcf for 1 h) followed by sonication. This step led to small (\~15 nm) MnO~2~ NPs stabilized with PAH (named colloidal MnO~2~).

Preparation of Ce6, DOX, and MnO~2~ Co-loaded Nanoparticles
-----------------------------------------------------------

The PCLA-PEG-PCLA-based nanoparticles were prepared by W/O/W emulsion solvent evaporation process [@B37], [@B40]. Briefly, 5 mg of DOX dissolved in 200 μL of the Tris-HCl solution (pH 8.0, 500 mM) and colloidal MnO~2~ (2.2 mg/mL, 500 μL) were mixed as the inner-water phase. The primary emulsion was generated by adding the above-mentioned solution to the mixture of PCLA-PEG-PCLA (20 mg/mL in ethyl acetate, 2 mL) and Ce6 (4 mg/mL in tetrahydrofuran, 0.5 mL), followed by sonicating using a probe-type ultrasonicator (Scientz-IID, Ningbo Scientz Biotechnology Co., Ltd, Ningbo, China). The primary emulsion was immediately transferred into 10 mL of Tris-HCl (pH 8.0, 10 mM) containing 1% PVA and sonicated again. Next, the organic solvent was removed by rotary evaporation under vacuum. The obtained CDM NPs were then centrifuged and filtered to discard the unloaded reagent. For the control groups, Ce6 and DOX co-loaded PCLA-PEG-PCLA nanoparticles (CD NPs) without MnO~2~, as the chemotherapy and photodynamic therapy system (combination therapy system) without O~2~ generation was prepared with the same method. Additionally, Ce6-loaded, DOX-loaded, Ce6-MnO~2~ co-loaded and DOX-MnO~2~ co-loaded nanoparticles, abbreviated as Ce6 NPs, DOX NPs, CM NPs, and DM NPs, respectively, were also obtained using the same protocol.

Characterization of the Co-loaded Nanoparticles
-----------------------------------------------

The size and zeta potential of the nanoparticles were acquired from dynamic laser scattering (DLS) measurements using a Malvern Zetasizer Nano-ZS (Zetasizer nano ZSP, Malvern, England). The morphology and size distribution were observed by transmission electron microscopy (TEM) using a Tecnai G2 F20 S-TWIN TEM (FEI Company, Hillsboro, OR, USA) at an accelerating voltage of 120 kV. The samples were prepared by dropping them on a copper grid followed by negative staining with 2.5% sodium phosphotungstic acid and drying at room temperature. The contents of DOX and Ce6 in these formulations were determined by UV-vis absorption spectroscopy. The loading percentage of MnO~2~ was measured using an inductively coupled plasma atomic emission spectrometer (ICP-AES, SPECTRO ARCOS, Spectro, Germany). UV-vis absorption spectra of blank NPs and various loaded nanoparticles were also measured.

Measurement of O~2~ Generation from MnO~2~ NPs *In Vitro*
---------------------------------------------------------

The O~2~ generated by MnO~2~ NPs was measured using a dissolved oxygen meter (JPBJ-608, INESA Scientific Instrument Co., Ltd, Shanghai, China). For this, in a sealed double-neck flask (wherein one neck contained a probe of the dissolved O~2~ meter immersed to the near bottom of the flask and sealed with a rubber plug), 100 mL of deoxygenated PBS 6.5 (0.1 M) or PBS 7.4 (0.1 M) was injected. Thereafter, 30% w/v H~2~O~2~ was injected into the flask to obtain the H~2~O~2~ solution with a concentration of 100 μM. The MnO~2~ NPs solution was injected into the flask after the readings recorded by the detector stabilized. Moderate shaking of the flask was maintained during the experiment. The values of the dissolved O~2~ detected by the probe were recorded at predetermined times.

Detection of ^1^O~2~ *In Vitro*
-------------------------------

The method for ^1^O~2~ detection by UV-vis spectroscopy was based on the protocol reported previously [@B37]. Briefly, 100 μL of ^1^O~2~ sensor 9, 10-anthracenediyl-bis (methylene) dimalonic acid (ABDA) solution (1 mg/mL) was mixed well with different Ce6 formulations (Ce6 = 10 μM) in deoxygenated PBS (pH 6.5 or 7.4), and H~2~O~2~ solution was added to maintain the final concentration of H~2~O~2~ at 100 μM. Then the solutions were irradiated by 660 nm light at a power density of 100 mW/cm^2^. The generated ^1^O~2~ was determined by measuring the absorbance change of ABDA at 378 nm under different laser-irradiation periods. ABDA in deoxygenated PBS (pH 6.5) under laser-irradiation was used as a control.

*In Vitro* Drug Release of DOX
------------------------------

The *in vitro* release behavior of DOX from the nanoparticles was investigated by a dialysis method. In brief, 1 mL of nanoparticle dispersions containing 1.0 mg of DOX were sealed in a dialysis bag (molecular weight cut-off 8000 \~14000). The bags were immersed in the release media containing 0 M or 100 μM of H~2~O~2~. The containers were placed in a shaking bed with a rotation speed of 100 rpm at 37 °C. All the release media consisted of 10 mL PBS (pH 7.4 or 6.5, 0.1 M). At predetermined time intervals, the release media was replaced with the same volume of fresh buffer. DOX released from samples was measured by UV-vis spectrometry.

Intracellular Uptake and Distribution
-------------------------------------

Intracellular drug distribution of CDM NPs was investigated by confocal laser scanning microscopy (CLSM). MCF-7 cells cultured for 24 h in glass-bottom dishes were treated with CDM NPs (DOX = 10 μg/mL and Ce6 = 5 μg/mL) in the dark for different incubation times (1, 2, and 4 h). Cells were washed three times with ice-cold PBS and fixed by 1 mL of immune staining fix solution for 20 min. The nuclei were stained with Hoechst 33342 (10 μg/mL) for 30 min and washed thoroughly with ice-cold PBS before fluorescence imaging (A1R MP+, Nikon Corporation, Tokyo, Japan).

To quantify the intracellular uptake of nanoparticles, flow cytometric analysis with an excitation laser at 633 nm was used. MCF-7 cells during the exponential growth phase were seeded in 6-well plates at a seeding density of 1×10^5^ cells per well and incubated for 24 h to allow cell attachment. The cultures were replaced with fresh serum-free media containing free Ce6, Ce6 NPs, or CM NPs at a concentration of 2 μM (Ce6) for 4 h. Subsequently, the cells were washed with PBS for flow cytometry measurement (CYTOMICS FC 500, Beckman Coulter, Brea, California, USA).

Intracellular ROS Detection and Apoptosis After Laser-irradiation
-----------------------------------------------------------------

MCF-7 cells were seeded at a density of 1×10^5^ cells per well in 12-well plates. After the cells were incubated for 24 h, the media was replaced with the fresh serum-free culture containing free Ce6, Ce6 NPs, or CM NPs. The final concentration of Ce6 was 500 nM. The cells were further incubated for 4 h and washed once with PBS, then incubated with 10 μM of 2\', 7\'-dichlorodihydrofluorescein diacetate (DCFH-DA, ROS-sensitive probe) for 20 min to detect the intracellular ROS generation followed by irradiation with a 660 nm laser (100 mW/cm^2^) for 5 min. After additional 30 min incubation, the cells were harvested, and the fluorescence was detected by flow cytometry (FITC channel) to measure the intracellular ROS level. The intracellular ROS was also detected by observing dichlorofluorescein (DCF) using confocal microscopy.

After treatment with free Ce6, Ce6 NPs, or CM NPs (500 nM of Ce6) for 4 h, MCF-7 cells were rinsed with culture media and photo-irradiated with a 660 nm laser (100 mW/cm^2^) for 5 min. At 4 h post irradiation, the cells were trypsinized and then stained with Annexin V-FITC Apoptosis Detection Kit according to the manufacturer\'s instruction. The fluorescence of FITC and propidium iodide (PI) was detected by flow cytometry.

Cytotoxicity Assay
------------------

To investigate the*in vitro* PDT effect of different Ce6 formulations, MCF-7 cells seeded in 96-well plates at a density of 1×10^4^ cells per well were cultured for 24 h and then treated with free Ce6, Ce6 NPs, and CM NPs for 4 h, which were then replaced with fresh culture media. Next, the cells were exposed to 660 nm light at a power density of 100 mW/cm^2^ for 5 min and further incubated for 24 h. The relative cell viabilities were measured and calculated by the standard MTT method. The cells incubated with identical Ce6 formulations but unexposed to laser were used as controls.

For combination therapy, MCF-7 cells were incubated with free DOX, DOX NPs, DM NPs, CD NPs (+laser), and CDM NPs (+laser). After 4 h of incubation, the cells in Ce6-treatment groups were exposed to 660 nm light at a power density of 100 mW/cm^2^ for 5 min, and further incubated for 24 h before MTT assay.

Animal Model
------------

Female Balb/c nude mice (6-8 weeks-old) were purchased from Beijing HFK Bioscience Co., Ltd (Beijing, China) and used under protocols approved by Sichuan University Laboratory Animal Center. Solid tumors of human breast cancer MCF-7 cells were grown by subcutaneous injection of 1 × 10^6^ cells suspended in 100 μL serum-free DMEM medium onto the back of each mouse. Tumor volume was measured using vernier calipers by measuring length and width and calculated using the following formula: 1/2×width^2^×length.

Fluorescence, PA, and MR Imaging *In Vitro* and *In Vivo*
---------------------------------------------------------

For fluorescence imaging, free Ce6/DOX (mixed solution of Ce6 and DOX), CD NPs, and CDM NPs were systemically administrated to tumor-bearing mice through the tail vein at a Ce6 dose of 2.5 mg/kg (DOX: 5 mg/kg, MnO~2~: 1 mg/kg). At predetermined time points, the mice were anesthetized, and fluorescence images were acquired on an IVIS Lumina III imaging system (Perkin Elmer, Caliper Life Sciences, MA, USA; excitation filter: 640 nm, emission filter: 710 nm). The mice were sacrificed at 24 h post-injection, and *ex vivo* imaging was performed on the excised tumors and organs.

PA imaging was conducted using a real-time multispectral optoacoustic tomography (MSOT) small animal scanner (inVision 128, iThera Medical GmbH, Neuherberg, Germany) at an excitation wavelength of 680 nm. CDM NPs at various concentrations in transparent polyethylene cylinders embedded in agar gel with a diameter of 2.0 cm were subjected to *in vitro* PA imaging. The averaged PA signal intensity was plotted against Ce6 concentration. For MSOT imaging *in vivo*, MCF-7 tumor-bearing mice were intravenously (i.v.) injected with 200 μL of free Ce6/DOX, CD NPs, and CDM NPs suspension at an identical Ce6 dose of 2.5 mg/kg, 5 mg/kg of DOX, and 1 mg/kg of MnO~2~ in the CDM NPs group. PA images of the tumor sites were acquired at different time points post-injection, and the PA signals were recorded.

For*in vitro* MRI, CDM NPs solutions with various Mn concentrations (0 to 1 mM) treated with 10 mM H~2~O~2~ at different pH values were scanned using a 7-T clinical MRI scanner (BioSpec 70/20 USR, Bruker Biospin Corporation, Billerica, MA, USA) at room temperature. *T*~1~-weighted MR signal intensity of each sample was acquired from MR images in the region of interest (ROI). The relaxation rate *r*~1~ (1/ *T*~1~) was then calculated from *T*~1~ values at different Mn^2+^ concentrations. For MRI *in vivo*, MCF-7 tumor-bearing nude mice were scanned with a 7-T clinical MR scanner equipped with a special animal imaging coil (GE Healthcare, USA), before and after i.v. injection with CDM NPs at a dose of 1 mg/kg (MnO~2~).

Fluorescence Immunostaining of Tumor Hypoxia
--------------------------------------------

MCF-7 Balb/c tumor-bearing nude mice (n = 3/group) were i.v. injected with MnO~2~ NPs or saline (control). After 24 h, animals received an intraperitoneal injection of hypoxia marker pimonidazole HCl solution (60 mg/kg) (Hypoxyprobe-1 plus kit, Hypoxyprobe Inc., USA), and were sacrificed 60 min later. Tumor tissues were quickly harvested, embedded in OCT medium, and snap frozen. Consecutive 5 μm sections were cut at the largest circumference of the tumor. After thawing, the sections were fixed in cold acetone for 10 min and incubated overnight at 4 ℃ with the FITC-labeled mouse monoclonal anti-pimonidazole antibody (clone 4.3.11.3; FITC-MAb1) diluted in PBS containing 0.1% bovine serum albumin c and 0.1% Tween 20. Subsequently, the sections were incubated for 90 min with anti-FITC HRP, followed by incubation with Hoechst 33342 for nuclei location. Slides were scanned with a fluorescence microscope (Olympus, Shinjuku, Tokyo, Japan) and images were analyzed with ImageJ 7.0 software.

Blood Biochemistry and Hematology Studies of MnO~2~ NPs
-------------------------------------------------------

Nine healthy female Balb/c mice randomly divided into three groups (n = 3/group) were i.v. injected with MnO~2~ NPs at a dose of 5 mg/kg (in terms of MnO~2~) and sacrificed at 1, 7, and 14-days post-injection. Three healthy female untreated mice were used as controls. 0.3 mL of blood was drawn from mice for blood biochemistry analysis and 0.1 mL for hematology assay.

Pharmacokinetics and Biodistribution *In Vivo*
----------------------------------------------

To investigate the pharmacokinetics of the nanoparticles, Sprague-Dawley rats were randomly divided into four groups (n=3). Each group was i.v. injected with 1.0 mL of free DOX, DOX NPs, CD NPs, or CDM NPs solution with an identical DOX concentration of 5.0 mg/kg. Blood samples were collected from the orbital venous plexus with a heparinized tube at 5, 15, 30 min, 1, 2, 4, 8, 24, and 36 h post-administration. The supernatant of the blood sample was collected by centrifugation at 2380 rcf for 10 min, and the DOX content in the supernatant was determined using HPLC measurement. The organ biodistribution of CDM NPs was examined using MCF-7 tumor-bearing nude mice. Mice were administrated with CDM NPs at a MnO~2~ dose of 1.0 mg/kg. Animals were sacrificed at 2, 8, 12, and 24 h post-injection. All major organs (i.e., heart, liver, spleen, lung, kidneys) and tumor were collected, weighed, and digested in aqua regia overnight. The organ biodistribution was measured by analyzing Mn concentration in each organ using ICP-AES.

*In Vivo* Chemo-Photodynamic Therapy
------------------------------------

MCF-7 tumor-bearing mice were randomly divided into eight groups when the tumors reached \~100 cm^3^ (n=5 for each group): (1) saline, (2) free DOX, (3) DOX NPs, (4) CD NPs, (5) CDM NPs, (6) CM NPs, (7) Ce6 NPs, and (8) DM NPs. The doses of DOX, Ce6, and MnO~2~ were 5 mg/kg, 2.5 mg/kg, and 1 mg/kg, respectively. Mice were administrated with corresponding formulations at days 0, 2, and 4. All Ce6-treated groups received 10 min of laser-irradiation (660 nm, 100 mW/cm^2^) at 24 h post-injection (laser was placed \~1 cm above the tumor). The tumor volume and body weight of each mouse were recorded during therapy. Mice were sacrificed on day 18, and the tumors were collected and weighed. Inhibition ratio (IR) was calculated as follows: IR (%) = \[(x - y) / x\] × 100 %, where x and y stand for the average tumor weight for the control group (saline) and treatment group, respectively.

To evaluate the apoptotic response in tumor tissues, Ki-67 and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-digoxigenin nick-end labeling (TUNEL) staining were applied. The major organs (heart, liver, spleen, lungs, and kidneys) were also collected and examined by hematoxylin and eosin (H&E) staining to evaluate the biosafety of the hybrid nanoparticles.

Statistical Analysis
--------------------

Results are presented as mean ± SD. One-way analysis of variance (ANOVA) was used to determine the significance of differences. Statistical significance was set at *p* \< 0.05 (∗*p* \< 0.05, ∗∗*p* \< 0.01, ∗∗∗*p* \< 0.001).

Results and Discussion
======================

Characterization of the Theranostic Nanoparticles
-------------------------------------------------

The PCLA-PEG-PCLA copolymer was successfully synthesized by ring-opening polymerization of ε-CL and LA in the presence of PEG and was confirmed by ^1^H-NMR and FT-IR (Figure [S1](#SM0){ref-type="supplementary-material"}and Table [S1](#SM0){ref-type="supplementary-material"}). Detailed information on the copolymer and its blank NPs by W/O/W double emulsion solvent evaporation process is summarized in Table [S2](#SM0){ref-type="supplementary-material"}. The successful synthesis of PCLA-PEG-PCLA and the blank NPs showed desirable particle size and narrow size distribution.

Colloidal MnO~2~ was synthesized in an aqueous solution by reducing KMnO~4~ in the presence of cationic polyelectrolyte PAH. TEM images showed that the diameter of colloidal MnO~2~ ranged from 10 nm to 20 nm, which is consistent with the DLS results (15.6 nm, Figure [S2](#SM0){ref-type="supplementary-material"}A, B). XPS and UV-vis absorption spectra of colloidal MnO~2~ further illustrated the successful formation of Mn (IV) O~2~ (Figure [S2](#SM0){ref-type="supplementary-material"}C, D). The hydrodynamic size of blank NPs formed by PCLA-PEG-PCLA was \~92 nm, and those of the drug-loaded nanoparticles were slightly larger (100-130 nm) (Figure [2](#F2){ref-type="fig"}C, Figure [S3](#SM0){ref-type="supplementary-material"}). Sizes obtained from TEM imaging showed a positive correlation with the DLS results, and the morphology of the nanoparticles (uniform spherical structure) was slightly changed after loading the drugs (Figure [2](#F2){ref-type="fig"}A, B).

The zeta potential of blank NPs was approximately -20 mV, permitting long-term stability of the nanoparticles in the blood circulation and avoiding severe cytotoxicity [@B41], [@B42]. Interestingly, in contrast to the bare colloidal MnO~2~, which showed high positive charge at +29 mV and poor colloidal stability in saline and cell culture media (containing 50% FBS), the encapsulated form, MnO~2~ NPs, were negatively charged (-5.1 mV) and resisted aggregation in both media, making them suitable for *in vivo* application (Figure [2](#F2){ref-type="fig"}D, Figure [S4](#SM0){ref-type="supplementary-material"}). No precipitate was observed even after 15 days, supporting the hypothesis that MnO~2~ was successfully loaded into the nanoparticles. After the therapeutic agents were loaded, the zeta potential was about -8.9 mV and the CDM NPs also showed excellent stability *in vitro* (Figure [S5](#SM0){ref-type="supplementary-material"}).

Next, the UV-vis absorption spectrum of CDM NPs was measured (Figure [3](#F3){ref-type="fig"}A). A broad distinctive peak present around 300-400 nm could be attributed to the surface plasmon band of MnO~2~. The characteristic peaks from both DOX (489 nm) and Ce6 (405 nm, 671 nm) were also observed. These results suggested successful encapsulation of DOX, Ce6 and MnO~2~ into the nanoparticles. Notably, a new and slight red shift in the absorption spectrum was observed at \~700 nm, which could be due to the close interaction between Ce6 and the nanoparticles. By adjusting the dose, the contents of DOX, Ce6, and MnO~2~ in different formulations were tuned to be identical at 9.5%, 4.7% and 1.8%, respectively, as determined by UV-vis absorption spectroscopy and ICP-AES (Table [S2](#SM0){ref-type="supplementary-material"}).

It is well recognized that the active metabolism of cancer cells and insufficient blood supply inside solid tumors not only result in acidification of TME but also lead to significantly increased H~2~O~2~ levels inside tumors. According to the MnO~2~-H~2~O~2~ reaction equation shown in Figure [S6](#SM0){ref-type="supplementary-material"}, MnO~2~ only serves as a catalyst to promote decomposition of H~2~O~2~ to generate O~2~ under neutral conditions [@B43]. However, in the mild acidic condition, MnO~2~ functions as both catalyst and reactant and can decompose to harmless, water-soluble Mn^2+^ ions and produce O~2~ by consuming the tumor metabolites (H~2~O~2~ and H^+^) [@B44]. Considering the reactivity of MnO~2~ with H~2~O~2~ and H^+^, we first studied the degradation of MnO~2~ NPs in different media (Figure [S7](#SM0){ref-type="supplementary-material"}). We found that MnO~2~ degraded rapidly at pH 6.5 in the presence of H~2~O~2~, and almost all MnO~2~ converted into colorless Mn^2+^ ions in 4 h. In contrast, MnO~2~ showed a limited change in other conditions. We subsequently investigated the O~2~ generation ability of H~2~O~2~ upon addition of MnO~2~ NPs at different pH values (6.5 or 7.4), with pure H~2~O~2~ and H~2~O~2~ in the presence of blank NPs as control groups. As expected, MnO~2~ NPs could trigger efficient O~2~ generation in H~2~O~2~ solution at both pH 6.5 and pH 7.4. The O~2~ generation at pH 7.4 was likely due to the catalytic activity of MnO~2~ for H~2~O~2~ decomposition. Notably, a distinctively higher amount of O~2~ was produced at pH 6.5 (Figure [3](#F3){ref-type="fig"}B). In the control study, H~2~O~2~ solution and blank NPs generated negligible O~2~.

Encouraged by the effective O~2~ generation of H~2~O~2~ in the presence of MnO~2~ NPs, we examined whether the produced O~2~ facilitated ^1^O~2~ generation during PDT. The generation of ^1^O~2~ produced by free Ce6, Ce6 NPs, and CM NPs at the same Ce6 concentration in the presence TME-relevant H~2~O~2~ concentration was measured by ^1^O~2~ indicator ABDA. The deoxygenated solution pH was adjusted to 6.5, and 100 μM of H~2~O~2~ was added to mimic the TME concentration. As expected, the free Ce6 and Ce6 NPs showed a weak change of ABDA absorbance with laser-irradiation for 5 min, indicating that only moderate amount of ^1^O~2~ was generated. In sharp contrast, the generation of ^1^O~2~ by H~2~O~2~ in the presence of CM NPs at pH 6.5 was remarkably higher, which was probably attributed to the additional O~2~ supply by H~2~O~2~ in the presence of MnO~2~ (Figure [3](#F3){ref-type="fig"}C, Figure [S8](#SM0){ref-type="supplementary-material"}). Therefore, the PDT efficiency of CM NPs is expected to be distinctively improved in the TME containing a certain amount of H~2~O~2~.

Next, we measured the release behavior of DOX from nanoparticles by a dialysis method. As shown in Figure [3](#F3){ref-type="fig"}D, in the absence of H~2~O~2~, there was slow release of DOX from nanoparticles compared to free DOX, indicating the sustained release property of the polymeric carrier for drug delivery. Conversely, after 96 h of incubation with 100 μM H~2~O~2~ in PBS 6.5, \~80% of DOX originally encapsulated within DM NPs was released into the media. This was probably attributed to the catalysis by MnO~2~ to quickly generate O~2~ gas in the media mimicking TME, causing rupture of the PCLA-PEG-PCLA shell and subsequent release of DOX [@B21].

*In Vitro* Antitumor Efficacy by Chemotherapy and Enhanced PDT Associated with O~2~ Generation
----------------------------------------------------------------------------------------------

MCF-7 cells incubated with CDM NPs for different periods of time were imaged by a confocal microscope to investigate the intracellular distribution (Figure [4](#F4){ref-type="fig"}A). Both DOX and Ce6 fluorescence inside the cells significantly enhanced with the increase of incubation time. Interestingly, although Ce6 fluorescence was mostly located in the cytoplasm after incubation for 4 h, DOX preferentially accumulated inside the nuclei over time, indicating the gradual intracellular DOX release from CDM NPs. The quantitative cellular uptake of nanoparticles was also studied using Ce6 as the fluorescence probe. MCF-7 cells were incubated with free Ce6, Ce6 NPs and CM NPs with the same concentration of Ce6 for 4 h. As illustrated in Figure [4](#F4){ref-type="fig"}B, the Ce6-loaded nanoparticles showed significantly enhanced uptake vs. free Ce6. Also, the comparable fluorescence intensities observed in cells treated with Ce6 NPs and CM NPs indicated that the introduction of MnO~2~ did not interfere with the fluorescence of Ce6.

We next examined the generation of ROS such as ^1^O~2~ during intracellular PDT. MCF-7 cells were treated with DCFH-DA, a non-fluorescent molecule that can passively diffuse into cells and be oxidized by ROS and ^1^O~2~ to produce a bright green fluorescence compound DCF. The resulting oxidatively stressed cells showed green fluorescence indicating enhanced ^1^O~2~ gained. As shown in Figure [5](#F5){ref-type="fig"}A, cells treated with free Ce6, Ce6 NPs, or CM NPs without laser-irradiation presented a weak intracellular ROS signal (green). The control group not treated with any Ce6 formulation was also dim with/without laser-irradiation. However, in free Ce6, Ce6 NPs, and CM NPs groups under laser-irradiation, the bright green fluorescence signals of DCF were notably enhanced, suggesting that Ce6 could generate ^1^O~2~ in the cells under irradiation. Among the laser-irradiated groups, weak fluorescence observed in the free Ce6 group was attributed to lower cellular uptake efficiency of Ce6. As expected, compared with the Ce6 NPs group, a significant increase in ^1^O~2~ production by CM NPs was observed due to the MnO~2~-triggered generation of O~2~ from H~2~O~2~ in TME. Flow cytometry analysis (Figure [5](#F5){ref-type="fig"}B, C) further revealed that the order of ROS level was CM NPs \> Ce6 NPs \> free Ce6, which was consistent with confocal microscopy. These results verified the better performance of CM NPs as the ^1^O~2~ producer.

To elucidate the contribution of O~2~-enhanced PDT to the phototoxicity, we examined the cell apoptosis by flow cytometry. Annexin V-FITC and PI were introduced to distinguish viable cells from apoptotic and necrotic cells. The results in Figure [6](#F6){ref-type="fig"} showed different cell populations (viable (Annexin V-FITC^-^/PI^-^), early apoptotic (Annexin V-FITC^+^/PI^-^), and late-stage apoptotic or dead (Annexin V-FITC^+^/PI^+^)) were induced by different treatments. With 660 nm laser irradiation at a power density of 100 mW/cm^2^ for 5 min, the CM NPs group was more effective at inducing apoptosis than free Ce6 and Ce6 NPs (54.1% vs. 36.04% and 35.40%) at 4 h post-irradiation. Given the ROS generation and apoptosis results above, the PDT efficiency was significantly improved using MnO~2~-based photosensitizer-encapsulated nanoparticles relevant to the TME inside tumors.

The *in vitro* antitumor efficacy was evaluated by the MTT assay. First, the biocompatibilities of blank NPs, colloidal MnO~2,~ and MnO~2~-loaded NPs were studied, as shown in Figure [S9](#SM0){ref-type="supplementary-material"}. In striking contrast to the strong toxicity of positively charged colloidal MnO~2~, after 24 h treatment with either blank NPs or MnO~2~ NPs at the stated concentrations, the viabilities of both NIH 3T3 and MCF-7 cells were above 85%, indicating the good biocompatibility of the carriers. This result also indicated that colloidal MnO~2~ was successfully encapsulated in nanoparticles to shield its positive charge. Furthermore, upon laser-irradiation (660 nm, 100 mW/cm^2^) for 5 min, the cells incubated with blank NPs showed no significant decrease in viability, suggesting the cytotoxicity was negligible at the studied power density. Next, the cell viability of MCF-7 cells was examined to determine the PDT efficiency. We observed no obvious dark cytotoxicity in cells treated with free Ce6, Ce6 NPs, or CM NPs for 24 h (Figure [7](#F7){ref-type="fig"}A). However, under laser-irradiation, the PDT efficiency of CM NPs was distinctly higher than that of free Ce6 or Ce6 NPs at different concentrations. The results were consistent with those of ROS generation and cell apoptosis. Subsequently, we compared the combined chemo-PDT efficacy with the single chemotherapy. As shown in Figure [7](#F7){ref-type="fig"}B, a dose-dependent inhibitory effect was observed in all groups. Compared to chemotherapy alone (free DOX, DOX NPs, or DM NPs), the combined treatment by CD NPs (+laser) without MnO~2~ offered more effective cancer cell killing. As expected, the combination therapeutic efficacy could be further enhanced with O~2~-generation (CDM NPs group with the laser) at all concentrations. The IC~50~ values of free DOX, DOX NPs, DM NPs, CD NPs (+laser) and CDM NPs (+laser) against MCF-7 cells were 2.42, 3.30, 3.01, 1.98 and 0.85 μg/mL, respectively. Therefore, CDM NPs with MnO~2~ producing O~2~ from H~2~O~2~ *in situ* appear to be an efficient agent to improve PDT, enhancing the chemotherapeutic efficacy of polymeric DOX formulations for combined therapy.

Fluorescence, PA, and MR Multimodal Imaging
-------------------------------------------

The ability of CDM NPs to perform multimodal tumor imaging was investigated in MCF-7 tumor-bearing nude mice. The mice were randomly grouped when the tumor volume reached 150 mm^3^ (n=3 for each group). Free Ce6/DOX, CD NPs, or CDM NPs were i.v. injected at an identical Ce6 dose of 2.5 mg/kg. As displayed in Figure [8](#F8){ref-type="fig"}A, whole-body fluorescence imaging showed that Ce6 fluorescence distributed widely throughout the body 4 h after i.v. injection of the three formulations. Later, both CD NPs and CDM NPs showed obvious tumor accumulation while the fluorescence signals detected in the free Ce6/DOX group faded away rapidly likely due to the rapid clearance of free small molecular compounds from blood circulation. The fluorescence at the tumor sites was still strong in mice treated with CD NPs or CDM NPs at 24 h post-injection. The semi-quantitative biodistribution of these formulations based on *ex vivo* imaging of tumors and major organs at 24 h post-injection further confirmed the higher tumor uptake and retention of CD NPs and CDM NPs because of their prolonged blood circulation (Figure [8](#F8){ref-type="fig"}B).

As expected, the CDM NPs showed Ce6 concentration-dependent PA imaging contrast ability at 680 nm (Figure [S10](#SM0){ref-type="supplementary-material"}), confirming that PA imaging can be used to analyze CDM NPs accumulation in tumors. The *in vivo* tumor accumulation of different formulations was studied by MSOT examination. The PA signal of Ce6 increased over time due to the intratumoral accumulation of nanoparticles, whereas signal in the free Ce6/DOX group showed weak tumor contrast (Figure [8](#F8){ref-type="fig"}C, D). The quantification of Ce6 signal (green) in tumors further indicated stronger tumor accumulation of nanoparticles (CD NPs and CDM NPs) than free Ce6/DOX at 24 h post-injection, which was in agreement with the fluorescence imaging results.

It was previously reported that PA imaging could be used to monitor the oxygenation status in tumors based on signals of oxygenated hemoglobin (HbO~2~) and deoxygenated hemoglobin (Hb) at 850 and 750 nm, respectively [@B45]-[@B48]. To study whether MnO~2~-loaded nanoparticles could relieve the tumor hypoxia and oxygenate Hb to HbO~2~, we tested the blood HbO~2~ level in tumors by PA imaging. As shown in Figure [8](#F8){ref-type="fig"}C, E, the blood HbO~2~ level in tumors after administration of CDM NPs showed a significant increase in the HbO~2~ intensity (red) while no obvious change was observed in tumors injected with free Ce6/DOX or CD NPs. The HbO~2~ intensity of the CDM group by PA imaging after 24 h was 3.5-fold and 3.3-fold greater than those of the free Ce6/DOX and CD NPs groups, respectively. Furthermore, by immunofluorescence staining of the tumor slices extracted from mice at 24 h post-injection, we further demonstrated MnO~2~ NPs could ameliorate the hypoxia inside the tumors. Tumor hypoxic areas and cell nuclei were stained with an anti-pimonidazole antibody (green) and Hoechst 33342 (blue) for confocal imaging (Figure [8](#F8){ref-type="fig"}F). Compared to the control group (saline), the tumor slices from mice treated with MnO~2~ NPs presented reduced green fluorescence, indicating that the tumor hypoxia was relieved, likely due to the decomposition reaction of endogenous tumor H~2~O~2~ into O~2~ triggered by MnO~2~. The produced O~2~ could oxygenate Hb, which was concentrated in the tumor site due to its hypoxic microenvironment. Such enhanced oxygenation in the TME was expected to relieve the hypoxia-associated resistance during PDT *in vivo*.

The *T*~1~-weighted MRI property of CDM NPs in TME was examined using a 7-T MRI instrument. As displayed in Figure [8](#F8){ref-type="fig"}G, the nanoparticles exhibited Mn concentration-dependent *T*~1~-weighted MRI performance under dispersing conditions mimicking *in vivo* TME (pH 6.5, H~2~O~2~). The longitudinal relaxivity (*r*~1~), which is a parameter of change in the spin-lattice relaxation rate (*T*~1~^-1^) per unit concentration, was calculated to be 6.43 mM^-1^s^-1^, a value higher than that of commercial *T*~1~ contrast agent Gd-DTPA (Magnevist®, *r*~1~ ≈ 3.40 mM^-1^s^-1^). This high value of *r*~1~ could probably be ascribed to the high reactivity between MnO~2~ and H~2~O~2~ in acidic condition to generate paramagnetic Mn^2+^. Subsequently, the *in vivo* MRI capacity was investigated in an MCF-7 tumor-xenografted mouse model. Tumor-bearing mice were administrated CDM NPs via tail vein, and the saline group was used as a control. As elucidated in Figure [8](#F8){ref-type="fig"}H, the contrast enhancement provided by CDM NPs was observed gradually over time. This enhanced contrast in the images originated from increasing accumulation of CDM NPs and generation of Mn^2+^ resulting from the acidic condition as well as the abundant H~2~O~2~ in tumor tissue [@B49]. These multimodal imaging results indicated that CDM NPs could act as a theranostic nanoplatform during tumor treatment.

Biosafety, Pharmacokinetics, Biodistribution, and Combined Chemo-photodynamic Therapeutic Efficacy *In Vivo*
------------------------------------------------------------------------------------------------------------

For the biomedical applications of the metal-organic nanoparticles (MnO~2~ NPs), we first investigated their potential *in vivo* toxicity. Healthy Balb/c mice were i.v. injected with MnO~2~ NPs at a dose of 5 mg/kg, which was five times higher than the therapeutic dose in our study, followed by sacrificed at 1, 7, and 14-days post-injection for blood biochemistry and complete blood panel analysis (n = 3). Three healthy mice were used as controls. Liver function markers including total protein (TP), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and aspartate aminotransferase (AST) and the kidney function marker urea nitrogen (BUN) as well as creatinine (CRE) were determined to be normal and not significantly different from the control group, suggesting no obvious hepatic or kidney disorder by MnO~2~ NPs nanoparticles *in vivo*. Hematology parameters including white blood cells (WBC), red blood cells, (RBC) and platelet count (PLT) were determined. Compared with the control group, all parameters were within the normal ranges in experimental mice (Figure [S11](#SM0){ref-type="supplementary-material"}).

The pharmacokinetics of the CDM NPs was investigated in Sprague-Dawley rats by examining the blood concentration of DOX using HPLC. Compared with free DOX, the CDM NPs significantly improved the maximal blood concentration (C~max~) and area under the curve of DOX (AUC~(0‑t)~) by 29-fold and 13-fold, respectively (Figure [9](#F9){ref-type="fig"}A and Table [S3](#SM0){ref-type="supplementary-material"}). Moreover, the quantitative biodistribution of Mn from CDM NPs in major organs and tumors was assessed by ICP-AES at 2, 8, 12, and 24 h post-injection. As shown in Figure [9](#F9){ref-type="fig"}B, CDM NPs had a decent tumor uptake of 14.16 %ID/g at 24 h.

Encouraged by the *in vitro* antitumor effect of CDM NPs, we next evaluated the *in vivo* antitumor efficacy using an MCF-7 tumor xenografted mouse model. The tumor-bearing mice were randomly grouped when the tumor volume reached 100 mm^3^ (n=5). Mice were then i.v. injected with 200 μL of different formulations and laser-irradiation was performed in Ce6-treated groups at 24 h post-injection. As elucidated in Figure [9](#F9){ref-type="fig"}C, fast tumor growth was observed in the saline group. Mice after combination therapy using CDM NPs under 660 nm laser irradiation showed the most effective tumor growth inhibition efficacy compared with various control groups including chemotherapy alone (free DOX, DOX NPs, or DM NPs) and PDT alone (Ce6 NPs or CM NPs), confirming the benefits of co-delivering drug combinations in a single nanoparticle formulation as opposed to using individual single-drug nanoparticles. Notably, because of the presence of MnO~2~ to relieve tumor hypoxia, treatment with CDM NPs appeared to be significantly more effective compared to that with CD NPs, which was also the combination therapy but without the assistance of O~2~ generation *in situ.* At the end of the treatment period, mice treated with CDM NPs showed the smallest sizes and lightest weights of tumors among the seven treated groups (Figure [9](#F9){ref-type="fig"}D, E). This result revealed that CDM NPs inhibited the tumor growth most efficiently and the inhibition ratio (IR) calculated by tumor weight was 92.35%, followed by CD NPs (73.92%), DM NPs (65.48%), CM NPs (56.23%), DOX NPs (55.84%), free DOX (53.69%), and Ce6 NPs (32.98%). The body weight was also recorded to evaluate systemic toxicity in mice. Compared with the saline group, the body weight of mice in the free DOX group significantly decreased indicating its severe systemic side effect as reported previously, while no notable change was found in the nanoparticle groups (Figure [S12](#SM0){ref-type="supplementary-material"}) [@B50]. Furthermore, the H&E staining of tissue sections of major organs showed no obvious tissue damage from treatment with CDM NPs compared to the saline group (Figure [S13](#SM0){ref-type="supplementary-material"}).

Immunohistochemical staining of tumor sections for Ki*-*67 antigen was employed to determine the extent of tumor cell proliferation (Figure [10](#F10){ref-type="fig"}A, B). Visually, tumor cells in the CDM NPs-treated group exhibited decreased Ki-67 expression indicating markedly reduced tumor cell proliferation after treatment. Moreover, the immunofluorescence TUNEL staining assay of tumors showed massive apoptotic tumor cells in the CDM NPs-treated group (apoptotic index 84.3%), while mice treated with the other groups exhibited far less apoptosis in tumor tissues (Figure [10](#F10){ref-type="fig"}C, D). With the chemo and photodynamic treatments, irreversible DNA/RNA and protein damage occurred, resulting in the inhibition of tumors. Thus, the *in vivo* study results validated CDM NPs as a potentially safe and efficient delivery platform for theranostics of malignant tumors.

Conclusion
==========

We have successfully fabricated multifunctional, intelligent, tumor microenvironment-responsive nanoparticles through a rather simple one-step double emulsion solvent evaporation process. The nanoparticles were used against breast cancer to simultaneously deliver DOX, Ce6, and MnO~2~ for combined chemo and photodynamic therapy enhanced by O~2~ generation. The Ce6-DOX-MnO~2~ (CDM) nanoparticles showed efficient passive tumor accumulation, induced decomposition of endogenous tumor H~2~O~2~ to produce O~2~ *in situ*, and improved tumor oxygenation to enhance the efficacy of photodynamic therapy used in combination with chemotherapy. The CDM nanoparticles displayed good potential for fluorescence, MRI, and PA triple-modal tumor imaging which could be an informative tool to monitor the distribution in the body and the therapeutic effects on tumors. Overall, the theranostic nanoagent fabricated by this simple process might provide comprehensive diagnostic information of the targeted tumor for more effective synergistic anticancer therapy.
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![**(A)** Schematic illustration of the hybrid polymeric system consisting of Ce6, DOX, and MnO~2~ co-loaded nanoparticles (CDM NPs) prepared by a double emulsion solvent evaporation method. **(B)** Schematic illustration of tumor-targeting CDM NPs for combined O~2~-generating chemo-photodynamic cancer therapy and trimodal fluorescence (FI), photoacoustic (PA) and magnetic resonance (MRI) imaging.](thnov08p1558g001){#F1}

![Physicochemical characterization of CDM nanoparticles. **(A-B)** Morphology of Blank NPs **(A)** and CDM NPs **(B)** under TEM. **(C)** Hydrodynamic diameters of Blank NPs, DOX NPs, Ce6 NPs, MnO~2~ NPs, and CDM NPs measured by dynamic light scattering (DLS). **(D)** Zeta potentials of Blank NPs, Colloidal MnO~2~, DOX NPs, Ce6 NPs, MnO~2~ NPs, and CDM NPs.](thnov08p1558g002){#F2}

![Physicochemical characterization of CDM nanoparticles. **(A)** UV-vis absorption spectra of Blank NPs, DOX NPs, Ce6 NPs, MnO~2~ NPs, and CDM NPs. **(B)** Oxygen generation in H~2~O~2~ solutions (100 × 10^-6^ M) with MnO~2~ NPs (100 × 10^-6^ M, in terms of MnO~2~) added at different pH values (7.4 and 6.5). **(C)** The generation of singlet oxygen determined by the change in ABDA absorbance for CM NPs at different pH values (7.4 and 6.5). **(D)** DOX-release profiles in the presence and absence of H~2~O~2~ at different pH values.](thnov08p1558g003){#F3}

![**(A)** Confocal fluorescence images of MCF-7 cells incubated with CDM NPs at various time points. Blue, green, and red represent DAPI, DOX, and Ce6 fluorescence, respectively. Scale bars correspond to 50 μm in all panels. **(B)** Flow cytometry analysis of MCF-7 cells incubated for 4 h with free Ce6, Ce6 NPs, and CM NPs, respectively.](thnov08p1558g004){#F4}

![Enhanced ^1^O~2~ production by CM NPs-mediated PDT in MCF-7 cells. **(A)** Confocal images of ROS generation by DCFH-DA staining in cells incubated with medium (control), control + laser, free Ce6, free Ce6 + laser, Ce6 NPs, Ce6 NPs + laser, CM NPs, and CM NPs + laser (blue for Hoechst, green for DCF; scale bar represents 50 μm). **(B)** Flow-cytometry analysis of ROS generation in cells with different treatments. **(C)** Quantitative analysis of the mean fluorescence intensity of ROS in MCF-7 cells. The data are shown as mean ± SD (n = 3), ∗ indicates *p* \< 0.05 vs. (CM NPs + laser).](thnov08p1558g005){#F5}

![Flow cytometric analysis of MCF-7 cells apoptosis at 4 h induced by different Ce6 formulations with laser irradiation, using Annexin V-FITC and PI staining. The concentration of Ce6 was 500 nM. ∗*p* \< 0.05.](thnov08p1558g006){#F6}

![*In vitro* chemo-photodynamic therapy in MCF-7 cells at 24 h. **(A)** Phototoxicity of free Ce6, Ce6, and CM NPs with or without laser irradiation (660 nm, 100 mW/cm^2^, 5 min). **(B)** Quantitative comparison of cytotoxicity following chemo (free DOX, DOX NPs, and DM NPs) and chemo-photodynamic combined treatments (CD NPs + laser, CDM NPs + laser). The data are shown as mean ± SD (n = 3). ∗*p* \< 0.05, ∗∗*p* \< 0.01 and ∗∗∗*p* \< 0.001.](thnov08p1558g007){#F7}

![**(A)** Fluorescence images of MCF-7 tumor-bearing mice post i.v. injection of different formulations; the bottom panel shows the *ex vivo* images of isolated organs and tumors examined at 24 h post-injection. **(B)** Semi-quantitative analysis of the mean fluorescence intensity in organs and tumors isolated at 24 h post-injection. **(C)** PA imaging of the tumor-bearing mice injected with different formulations. **(D)** Time course PA signal quantifications of Ce6 at 680 nm. **(E)** Time course PA signal quantifications of oxygenated hemoglobin (HbO~2~) at 850 nm. **(F)** Confocal immunofluorescence images of tumor slices collected from mice 24 h post-injection of saline or MnO~2~ NPs after hypoxia staining. The nuclei and hypoxic areas were stained by Hoechst 33342-stained (blue) and anti-pimonidazole antibody (green), respectively. Scale bar: 100 μm. **(G)** *In vitro T*~1~-weighted MRI properties of CDM NPs at different Mn concentrations after H~2~O~2~ (100 μM) treatment in either mildly acidic environment (pH = 6.5) or neutral conditions (pH = 7.4). **(H)** *T*~1~-weighted MR images of MCF-7 tumor-bearing mice before and after injection with CDM NPs. ∗*p* \< 0.05 and ∗∗∗*p* \< 0.001.](thnov08p1558g008){#F8}

![**(A)** Pharmacokinetics of different DOX formulations at a DOX dose of 5 mg/kg in Sprague-Dawley rats. **(B)** Organ distribution of CDM NPs in MCF-7 tumor-bearing nude mice. **(C)** Tumor growth curves of various groups. Three injections on days 0, 2, and 4 were given, and 660 nm laser irradiation was performed at 24 h post-injection for 10 min. **(D)** Final tumor weights after 18 days. Scale bar: 1 cm. **(E)** Images of the tumors collected from various groups of mice at the end of the treatments (day 18). Error bars represent the standard deviations of 5 mice per group. ∗*p* \< 0.05, ∗∗*p* \< 0.01 and ∗∗∗*p* \< 0.001.](thnov08p1558g009){#F9}

![Histological analysis of tumor slices after Ki-67 staining **(A)** and TUNEL assay **(C)**. Scale bars are 100 μm. **(B)** The corresponding proliferation index of the tumor tissue in the Ki-67 staining assay. **(D)** The percentage of apoptotic cells after treatment. Data are expressed as mean ± SD (n = 3). ∗*p* \< 0.05 and ∗∗*p* \< 0.01.](thnov08p1558g010){#F10}
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